

Case report

Through Indian Eyes: A Case Series on Steroid-Induced Secondary Cataract

ABSTRACT

Lichen planus, a chronic autoimmune dermatological disorder, often necessitates the use of topical corticosteroids for symptom management. However, this case series highlights the emergence of topical steroid-induced secondary cataracts in two patients, emphasizing a previously underrecognized complication. Both patients, females aged 36 and 43, presented with gradual vision loss in their left eyes, attributed to prolonged corticosteroid use for lichen planus and skin allergies, respectively. Ophthalmological examinations confirmed the diagnosis, leading to cataract surgeries. The pathogenesis involves complex cellular and molecular mechanisms, emphasizing the need for vigilant monitoring during corticosteroid therapy. Moreover, the lack of stringent reporting systems for adverse drug reactions in India underscores the necessity for comprehensive monitoring to mitigate economic and quality of life burdens. The study emphasizes the importance of judicious corticosteroid use, tapering regimens, and patient education to minimize complications while effectively managing dermatological conditions. This underscores the critical need for heightened awareness, surveillance, and patient-centred approaches to mitigate the risk of corticosteroid-induced secondary cataracts, ensuring optimal therapeutic outcomes and long-term ocular health.

INTRODUCTION

Lichen Planus is a chronic autoimmune inflammatory dermatological disorder that affects both mucosal and cutaneous layers with a global prevalence ranging from 0.5% to 1.0%.^{1,2} This condition manifests as T cell-mediated lipogenic plaques characterized by flat-topped, polygonal, and irritating papules that may aggregate to form plaques.³ Given its prominent visibility on the skin, lichen planus can create a social stigma, emphasizing the critical need for effective medication to alleviate symptoms and address the emotional impact on individuals dealing with this dermatological condition.¹

Cataract is a prevalent ocular ailment marked by the gradual clouding of the lens and subsequent vision impairment that stands as the leading treatable contributor to acquired blindness on a global scale.⁴ Its prevalence escalates with advancing age, ranging from 3.9% among individuals aged 55–64 years to a staggering 92.6% among those aged 80 years and above.⁴ In India, studies have indicated that monotype subtype cataracts account for 32% and 25% of cases in rural and urban populations, respectively, while mixed cataracts represent 12.68% and 18.6% of cases, respectively.⁵ Oral and topical corticosteroids serve as primary therapeutic agents in managing lichen planus symptoms.⁶ However, prolonged use of these corticosteroids has been associated with various ocular side effects, with cataract formation and changes in intraocular pressure being the most common.⁷ Cataracts involve intricate molecular and cellular processes within the eye's lens, ultimately leading to a loss of transparency and visual impairment.⁸ **Steroid-induced**

cataract poses a significant concern for individuals undergoing long-term corticosteroid therapy. Prolonged exposure to corticosteroids, whether systemic or inhaled, can disrupt lens metabolism, leading to the formation of opacities and subsequent visual impairment. While the exact mechanisms remain incompletely understood, the risk of cataract development is influenced by factors such as dosage, duration, and route of administration of corticosteroids.

In this case series, two patients developing Topical steroids-induced secondary cataract is presented. Limited information exists on the relationship between topical corticosteroids and cataracts, making this case particularly noteworthy. This underscores the importance of continuous vigilance regarding potential side effects associated with prolonged topical corticosteroid use and emphasizes the need for further research to enhance our understanding of such complications, contributing to more informed therapeutic decisions.

CASE 01:

A 36-year-old female presented to the ophthalmology OPD with a complaint of gradual diminution of vision in her left eye over the past year. Initially insidious and painless, the progression led to a hazy view, significantly disrupting her daily routine. Notably, there were no associated symptoms of redness or watery discharge. Birth and family histories were found to be insignificant. The patient had been diagnosed with lichen planus a year ago, prompting the initiation of topical corticosteroid treatment. Specifically, she had been using a skin cream containing clobetasol propionate, miconazole nitrate, and neomycin sulfate (0.1%, 20g) for the past eight years, applying it 2-3 times daily during episodes of increased itching on the affected areas, specifically on lower limbs and oral cavity. No other medications were reported to be administered by the patient.

Upon ophthalmological examination, her right eye exhibited a visual acuity of 6/6, while her left eye had a visual acuity limited to counting fingers at 3 meters. Intraocular lens measurements revealed +22.00 for the right eye and +21.50 for the left eye (Figure 1). Upon inquiring the medication history and through evaluation of the patient condition, the diagnosis pointed towards topical corticosteroid-induced secondary cataract in the left eye. In line with this, the patient was recommended for manual small incision cataract surgery. For preoperative care, she was prescribed tropicamide and phenylephrine eye drops every 10 minutes along with Tab. Ciprofloxacin 500mg BID, Moxifloxacin eye drops and Flurbiprofen eye drops QID for the left eye. This comprehensive approach aimed to address the ocular manifestations resulting from prolonged use of topical corticosteroids and to facilitate a successful cataract surgery outcome.



Figure 1: Cataracted Eye in a Photographic Objective

CASE 02:

A 43-year-old female presented with a complaint of gradual and painless diminution of vision in her left eye over the past 3 months. Notably, there was no history of redness, watery discharge, or trauma. The patient has a medical history of hypertension for the last 3 years, managed with medication (Tab. Telmisartan 40mg OD). Additionally, she reported a history of both oral and topical steroid use for a dermatologic condition i.e., Lichen Planus over the last 3 years. Upon inquiry, it was discovered that she intermittently took Tablet Prednisolone 20mg 1-0-1 under medical guidance only during symptom exacerbations. Additionally, she reported using Topical Clobetasol Phosphate 0.1% BID on the affected areas, primarily on the face and lower back, during episodic periods. Her last application was one month prior to admission with the aforementioned complaints. Apart from Tab. Telmisartan 40mg OD, there were no other concurrent medications. Ophthalmological examination revealed normal visual acuity in the right eye (6/6) but a diminished visual acuity in the left eye (6/18). Similar to the previous case, the diagnosis pointed towards the steroid-induced secondary cataract. Consequently, the patient was scheduled for cataract surgery, and the postoperative period transpired uneventfully.

DISCUSSION

Steroid-induced cataract involves multiple complex processes at the cellular and molecular levels. The process begins with the binding of steroids, both endogenous and exogenous, to intracellular glucocorticoid receptors. This binding triggers alterations in gene expression, affecting genes crucial for maintaining lens structural integrity. Subsequently, changes in protein synthesis contribute to cataract formation. Steroids induce oxidative stress within lens cells, leading to increased reactive oxygen species (ROS) levels, damaging cellular structures such as proteins and lipids. Chronic exposure compromises antioxidant defense mechanisms, crucial for neutralizing ROS and preventing oxidative damage. Steroids also influence protein aggregation

and glycation, contributing to the formation of clusters that compromise lens transparency. Alterations in the extracellular matrix, lens epithelial cell changes, and disruptions in fluid and ion balance may further contribute to opacification. It's also very important to note that the exact mechanisms may vary based on factors like steroid type, dose, and duration, as well as individual patient characteristics.^{9,10}

In this particular case, the onset of an inflammatory condition emerged as an unintended consequence of the drug administered for the primary illness, notably without any pre-existing ocular issues in the patient's medical history. The utilization of low-dose corticosteroids is a common practice in managing inflammatory, autoimmune, and allergy disorders.⁹ While the use of steroids becomes imperative in chronic allergic dermatological conditions, it is crucial to adopt a vigilant approach by closely monitoring the patient's response. The judicious reduction of dosage or application frequency is advised to strike a balance between therapeutic efficacy and minimizing potential adverse effects.

Besides topical and oral corticosteroid usage, the latest meta-analysis comprising 19 studies revealed a twofold increase in the risk of cataract among asthma and COPD patients exposed to corticosteroids. This study underscored the previously underestimated long-term ophthalmologic risks associated with inhaled corticosteroid (ICS) therapy.¹¹ As concerns regarding steroid use heighten, a study assessed the level of knowledge and awareness concerning steroid-induced cataracts among the general public, concluding that most participants exhibited inadequate understanding.¹² Despite cataracts being commonly associated with aging, posterior cataracts were observed even in children with frequent relapses or steroid-dependent nephrotic syndrome, contributing to 14.9%.¹³ This emphasizes the significance of ophthalmologic health in steroid-dependent conditions. Furthermore, ongoing advancements aim to prevent steroid-induced cataracts, including research in the field of Ayurvedic medicine. One study highlighted the protective effects of ethanolic extracts of *Piper betle* leaves against dexamethasone-induced cataracts in isolated goat lenses, suggesting anti-cataractogenic properties.¹⁴ Additionally, research suggests the potential of 'chondroitin sulfate proteoglycan 5' as a therapeutic target for preventing and treating steroid-induced cataracts, using dexamethasone-treated human lens epithelial cells and lens epithelium from anterior capsules of patients with steroid-induced cataracts obtained during cataract surgery.¹⁵ Numerous breakthrough studies are underway to mitigate cataract occurrence in steroid-dependent patients.

It's noteworthy that in India, there is a lack of stringent norms pertaining to the reporting and follow-up of adverse drug reactions. The prevailing approach often centers on managing patient complaints rather than investigating the root cause and educating healthcare professionals. This paradigm may inadvertently contribute to an economic burden on the patient, exacerbating the already compromised quality of life. The cumulative impact, encompassing both medical and non-medical costs, underscores the need for a comprehensive monitoring system to not only ensure optimal medication management but also to preemptively address any adverse reactions.

Such an approach not only safeguards the patient's quality of life but also mitigates the economic burden associated with prolonged medication use, promoting a more holistic and patient-centric healthcare model. Furthermore, in order to raise awareness about adverse drug reactions in India, the Pharmacovigilance Programme of India (PvPI) was initiated in 2008. There is a pressing need for increased awareness about PvPI among healthcare providers throughout the country.

CONCLUSION

This case study delves into the intricate realm of topical steroid-induced cataracts, shedding light on a patient's journey where the pursuit of well-being unexpectedly manifested in a visual complication. Prolonged use of topical corticosteroids emerges as a significant factor contributing to the development of secondary cataracts, posing a challenge in the treatment of individuals undergoing steroid therapy for diverse medical conditions.

Abrupt cessation of corticosteroid therapy carries the risk of a rebound effect, exacerbating inflammation and potentially elevating intraocular pressure. Contrarily, a tapered approach allows for a gradual reduction in medication, minimizing the likelihood of adverse effects while effectively managing the underlying ocular condition in a controlled manner. To mitigate the risk of complications, utmost caution is warranted in prescribing topical corticosteroids, necessitating comprehensive patient education on proper tapering techniques. Ensuring that medical professionals provide detailed guidance on tapering regimens establishes a careful equilibrium, optimizing therapeutic benefits while safeguarding long-term visual well-being. This emphasizes the critical role of patient education and adherence to tapering protocols in maintaining a delicate balance between the advantages of therapy and sustained ocular health.

References:

1. Solimani F, Forchhammer S, Schloegl A, Ghoreschi K, Meier K. Lichen planus - a clinical guide. *J Dtsch Dermatol Ges.* 2021 Jun;19(6):864-882. doi: 10.1111/ddg.14565. Epub 2021 Jun 7. PMID: 34096678.
2. Gupta MK, Lipner SR. Review of Nail Lichen Planus: Epidemiology, Pathogenesis, Diagnosis, and Treatment. *Dermatol Clin.* 2021 Apr;39(2):221-230. doi: 10.1016/j.det.2020.12.002. Epub 2021 Feb 10. PMID: 33745635.
3. Boch K, Langan EA, Kridin K, Zillikens D, Ludwig RJ and Bieber K (2021) Lichen Planus. *Front. Med.* 8:737813. doi: 10.3389/fmed.2021.737813
4. Fang R, Yu YF, Li EJ, Lv NX, Liu ZC, Zhou HG, Song XD. Global, regional, national burden and gender disparity of cataract: findings from the global burden of disease study 2019. *BMC Public Health.* 2022 Nov 12;22(1):2068.
5. Singh S, Pardhan S, Kulothungan V, Swaminathan G, Ravichandran JS, Ganesan S, Sharma T, Raman R. The prevalence and risk factors for cataract in rural and urban India. *Indian journal of ophthalmology.* 2019 Apr 1;67(4):477-83.

6. Kramer M, Tomkins-Netzer O. Cataract Risk and Topical Corticosteroids among Children with Juvenile Idiopathic Arthritis-Related Uveitis. *Ophthalmology*. 2020 Apr;127(4S):S19-S20. doi: 10.1016/j.ophtha.2019.10.042. PMID: 32200820.
7. Delbarre M, Froussart-Maille F. Sémiologie et formes cliniques de la cataracte chez l'adulte [Signs, symptoms, and clinical forms of cataract in adults]. *J Fr Ophtalmol*. 2020 Sep;43(7):653-659. French. doi: 10.1016/j.jfo.2019.11.009. Epub 2020 Jun 22. PMID: 32586638.
8. Carlson J, McBride K, O'Connor M. Drugs associated with cataract formation represent an unmet need in cataract research. *Frontiers in Medicine*. 2022 Aug 15;9:947659.
9. Lim SY, Bolster MB. Corticosteroids. *Neurorheumatology: A Comprehensive Guide to Immune Mediated Disorders of the Nervous System*. 2019:261-7.
10. Tatham A. Atopic dermatitis, cutaneous steroids and cataracts in children: two case reports. *J Med Case Rep*. 2008 Apr 28;2:124. doi: 10.1186/1752-1947-2-124. PMID: 18442376; PMCID: PMC2383898.
11. Savran O, Suppli Ulrik C. Inhaled Corticosteroid Exposure and Risk of Cataract in Patients with Asthma and COPD: A Systematic Review and Meta-Analysis. *Journal of Ophthalmology*. 2023 Oct 19;2023.
12. Bamahfouz A, Elmorsy S, Alharbi ER, Bakry SM, Alnemari W, Alzahrani SM, Almousa AA, Emorsy S, Alharbi II ER. Assessment of the Level of Knowledge and Awareness of the Risk of Chronic Use of Steroids in Causing Cataracts Among the General Population in the Western Region of the Kingdom of Saudi Arabia (KSA): A Cross-Sectional Study. *Cureus*. 2024 Jan 15;16(1).
13. Shabbir K, Anjum M, Naeem B, Urooj H. Frequency of posterior cataract in steroid-dependent or frequent relapse nephrotic syndrome in children. *The Professional Medical Journal*. 2023 Nov 1;30(11):1436-41.
14. Metla P, Moka S, Midde V. Anti-cataract Potential of Piper Betle Leaf Ethanol Extract on Dexamethasone-Induced Cataract. *Journal of Pharma Insights and Research*. 2024 Feb 8;2(1):164-8.
15. Yoo WS, Seong H, Song C, Choi MY, Lee B, Eom Y, Kim HJ, Yun SP, Kim SJ. Role of Chondroitin Sulfate Proteoglycan 5 in Steroid-Induced Cataract. *Cells*. 2023 Jun 23;12(13):1705.